While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year ...
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, ...
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: When was the last time you recovered money for shareholders?